araag2/TREC_Precision-Medicine huggingface dataset:
Patient case: 67-year-old female with Breast cancer. Genetic variant: FGFR1 Amplification, PTEN (Q171). Other conditions: Depression, Hypertension, Heart Disease.

Clinical trial: A Phase I Study of TQ-B3234 on Tolerance and Pharmacokinetics

Summary: To study the pharmacokinetic characteristics of TQ-B3234 in the human body, recommend a reasonable regimen for subsequent research.


Eligibility: Inclusion Criteria:
  -  Histological documentation of Advanced solid tumors,such as Malignant Melanoma,Colorectal Cancer,Pancreatic Carcinoma,Thyroid Carcinoma
  -  Lack of the standard treatment or treatment failure
  -  18-65 years,ECOG PS:0-1,Life expectancy of more than 3 months
  -  Main organs function is normal
  -  Stop other previous chemotherapy drugs more than 4 weeks
  -  Women of childbearing potential should agree to use and utilize an adequate method of contraception (such as intrauterine device，contraceptive and condom) throughout treatment and for at least 6 months after study is stopped；the result of serum or urine pregnancy test should be negative within 7 days prior to study enrollment，and the patients required to be non-lactating；Man participants should agree to use and utilize an adequate method of contraception throughout treatment and for at least 6 months after study is stopped
  -  Patients should participate in the study voluntarily and sign informed consent
  Exclusion Criteria:
  -  Patients participated in other anticancer drug clinical trials within 4 weeks or Patients participating in other clinical trials now
  -  Blood pressure unable to be controlled(systolic pressure>140 mmHg，diastolic pressure>90 mmHg). Patients with Grade 1 or higher myocardial ischemia, myocardial infarction or malignant arrhythmias(including QTc≥440ms)
  -  Patients with non-healing wounds or fractures
  -  Patients with drug abuse history and unable to get rid of or Patients with mental disorders
  -  History of immunodeficiency
  -  Patients with concomitant diseases which could seriously endanger their own safety or could affect completion of the study according to investigators' judgment

Relevance to patient case: not relevant
Patient case: 67-year-old female with Breast cancer. Genetic variant: FGFR1 Amplification, PTEN (Q171). Other conditions: Depression, Hypertension, Heart Disease.

Clinical trial: A Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

Summary: The purpose of this study is to evaluate the efficacy and safety of INCB054828 in subjects with myeloid/lymphoid neoplasms with fibroblast growth factor receptor (FGFR) 1 rearrangement.


Eligibility: Inclusion Criteria:
  -  Documented lymphoid or myeloid neoplasm with 8p11 rearrangement known to lead to FGFR1 activation, based on standard diagnostic cytogenetic evaluation performed locally, before signing informed consent for this study.
  -  Subjects must be relapsed/refractory. Prior stem cell transplantation is allowed.
  -  Life expectancy ≥ 12 weeks.
  -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.
  Exclusion Criteria:
  -  Prior receipt of a selective FGFR inhibitor.
  -  History and/or current evidence of ectopic mineralization/calcification, including but not limited to soft tissue, kidneys, intestine, myocardia, or lung, except calcified lymph nodes and asymptomatic arterial or cartilage/tendon calcifications.
  -  Current evidence of corneal disorder/keratopathy, including but not limited to bullous/band keratopathy, corneal abrasion, inflammation/ulceration, and keratoconjunctivitis, as confirmed by ophthalmologic examination.
  -  Use of any potent cytochrome P450 3A4 inhibitors or inducers within 14 days or 5 half-lives (whichever is shorter) before the first dose of study drug.

Relevance to patient case: not relevant
Patient case: 67-year-old female with Breast cancer. Genetic variant: FGFR1 Amplification, PTEN (Q171). Other conditions: Depression, Hypertension, Heart Disease.

Clinical trial: A Phase I Study of TQ-B3101 on Tolerance and Pharmacokinetics

Summary: To study the pharmacokinetic characteristics of TQ-B3101 in the human body, recommend a reasonable regimen for subsequent research.


Eligibility: Inclusion Criteria:
  -  Histological documentation of Advanced solid tumors
  -  Lack of the standard treatment or treatment failure
  -  18-70years,ECOG PS:0-1,Life expectancy of more than 3 months
  -  Main organs function is normal
  -  Women of childbearing potential should agree to use and utilize an adequate method of contraception (such as intrauterine device，contraceptive and condom) throughout treatment and for at least 6 months after study is stopped；the result of serum or urine pregnancy test should be negative within 7 days prior to study enrollment，and the patients required to be non-lactating；Man participants should agree to use and utilize an adequate method of contraception throughout treatment and for at least 6 months after study is stopped
  -  Patients should participate in the study voluntarily and sign informed consent
  Exclusion Criteria:
  -  Patients with treatment failure by ALK/ROS1 inhibitor
  -  Patients with anti-teratment,radiotherapy or surgery within 4 weeks
  -  Patients participated in other anticancer drug clinical trials within 4 weeks or ALK/ROS1 inhibitor within 1 week
  -  Blood pressure unable to be controlled(systolic pressure>140 mmHg，diastolic pressure>90 mmHg). Patients with Grade 1 or higher myocardial ischemia, myocardial infarction or malignant arrhythmias(including QT≥470ms)
  -  Patients with non-healing wounds or fractures
  -  Patients with drug abuse history and unable to get rid of or Patients with mental disorders
  -  History of immunodeficiency
  -  Patients with concomitant diseases which could seriously endanger their own safety or could affect completion of the study according to investigators' judgment

Relevance to patient case: not relevant
Patient case: 67-year-old female with Breast cancer. Genetic variant: FGFR1 Amplification, PTEN (Q171). Other conditions: Depression, Hypertension, Heart Disease.

Clinical trial: Parathyroid Cancer Versus Atypical Parathyroid Neoplasm; Investigating Their Clinical Characteristics and Biological Behavior

Summary: Objectives:
  1. Identify the clinical characteristics of parathyroid (PTH) cancer and PTH atypical neoplasms
  2. Investigate if PTH carcinoma and atypical neoplasm present a biological behaviour and have a different impact on the health of the patients

Detailed description: Data between the years of 1/1/2002 and 12/31/2013 will be analyzed. The medical records of all adult patients that had a parathyroidectomy for primary PHPT in MD Anderson Cancer Center will be screened in order to identify patients that had a histopathological diagnosis of parathyroid carcinoma or atypical parathyroid neoplasm.

Eligibility: Inclusion Criteria:
  -  All patients from MDACC diagnosed with PHPT that have a histopathological diagnosis of PTH carcinoma or atypical parathyroid neoplasm between the years 1/1/2002 and 12/31/2013
  Exclusion Criteria:
  -  Pediatric patients
  -  Cases with incomplete records
  -  Patients where the follow-up will be less than six months

Relevance to patient case: not relevant
Patient case: 67-year-old female with Breast cancer. Genetic variant: FGFR1 Amplification, PTEN (Q171). Other conditions: Depression, Hypertension, Heart Disease.

Clinical trial: A Phase I Study of TQ-B3139 on Tolerance and Pharmacokinetics

Summary: To study the pharmacokinetic characteristics of TQ-B3139 in the human body, recommend a reasonable regimen for subsequent research.


Eligibility: Inclusion Criteria:
  -  Histological documentation of Advanced solid tumors
  -  Lack of the standard treatment or treatment failure
  -  18-65years,ECOG PS:0-1,Life expectancy of more than 3 months
  -  Patients with anti-treatment or surgery within 4 weeks
  -  Main organs function is normal
  -  Women of childbearing potential should agree to use and utilize an adequate method of contraception (such as intrauterine device，contraceptive and condom) throughout treatment and for at least 6 months after study is stopped；the result of serum or urine pregnancy test should be negative within 7 days prior to study enrollment，and the patients required to be non-lactating；Man participants should agree to use and utilize an adequate method of contraception throughout treatment and for at least 6 months after study is stopped
  -  Patients should participate in the study voluntarily and sign informed consent
  Exclusion Criteria:
  -  Patients participated in other anticancer drug clinical trials within 4 weeks
  -  Blood pressure unable to be controlled(systolic pressure>140 mmHg，diastolic pressure>90 mmHg).
  Patients with Grade 1 or higher myocardial ischemia, myocardial infarction or malignant arrhythmias(including QT≥470ms)
  -  Patients with non-healing wounds or fractures
  -  Patients with drug abuse history and unable to get rid of or Patients with mental disorders
  -  History of immunodeficiency
  -  Patients with concomitant diseases which could seriously endanger their own safety or could affect completion of the study according to investigators' judgment

Relevance to patient case: not relevant
Patient case: 67-year-old female with Breast cancer. Genetic variant: FGFR1 Amplification, PTEN (Q171). Other conditions: Depression, Hypertension, Heart Disease.

Clinical trial: Aerobic and Strength Training Exercise in Improving Fitness and Arm Health During and After Radiation Therapy in Patients With Stage II-III Breast Cancer

Summary: This randomized pilot phase I/II trial studies how well aerobic and strength training exercise works in improving fitness and arm health during and after radiation therapy in patients with stage II-III breast cancer. Aerobic and strength training exercise training during and after radiation therapy may reduce treatment related toxicities and improve adherence to exercise long term in patients with breast cancer.

Detailed description: PRIMARY OBJECTIVES:
  I. To determine the feasibility of conducting an exercise program during and after radiation therapy and to determine what percent of patients will complete the exercise program. (Pilot) II. To determine the percent increase in fitness as measured by the 6 minute walk test in women receiving radiation therapy for breast cancer randomized to an exercise program at 1 year. (Phase II)
  SECONDARY OBJECTIVES:
  I. Percent adherence to exercise at 1 year as measured by the International Physical Activity Questionnaire and exercise logs.
  II. Subjective arm health at 1 year as measured by Functional Assessment of Cancer Therapy Questionnaire for Breast Cancer version 4 (FACT-B+4).
  III. Arm lymphedema at 1 year as measured by arm circumference. IV. Arm range of motion at 1 year as measured by goniometry. V. Quality of life at 1 year as measured by FACT-B+4. VI. Percent increase in arm strength as measured by one repetition maximum at 1 year.
  VII. Change in weight and body mass index (BMI) 1 year after completion of radiation.
  OUTLINE: Patients are randomized to 1 of 2 arms.
  ARM I: Patients receive usual care for 6 weeks during radiation therapy and for 12 weeks after completion of radiation therapy.
  ARM II: Patients undergo a supervised aerobic and strength training exercise session over 40-60 minutes 3 times weekly for 6 weeks during radiation therapy and for 12 weeks after completion of radiation therapy.
  After completion of study, patients are followed up at 1 and 6 months, and 1 year.

Eligibility: Inclusion Criteria:
  -  Stage II-III breast cancer
  -  Prior surgery including lumpectomy or mastectomy and sentinel node biopsy or axillary lymph node dissection
  -  Prior chemotherapy in the neoadjuvant or adjuvant setting
  -  Radiation plan consisting of regional nodal radiation
  -  Must be suitable for an exercise program
  Exclusion Criteria:
  -  Serious underlying medical comorbidity such as uncontrolled hypertension, cardiovascular disease, pulmonary disease, psychiatric illness, or any other condition for which the patient is not approved for exercise by their physician
  -  Physical handicap that would prevent participation in program
  -  Patients with metastatic breast cancer

Relevance to patient case: not relevant
Patient case: 45-year-old female with Melanoma. Genetic variant: BRAF (V600E), CDKN2A Deletion. Other conditions: None.

Clinical trial: A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant

Summary: This is a phase I study of melanoma tumor antigen peptide vaccines. The nine amino acid peptides representing HLA-A2 restricted T cell epitope of the melanoma antigen, gp100 will be administered to patients emulsified in Incomplete Freund's Adjuvant, (IFA). The study is designed to evaluate the toxicity, immunologic effects and potential therapeutic role of repeated doses of gp100 peptide vaccines administered subcutaneously.
  Immune reactivity to the gp100 epitope peptides will be monitored in all patients by analysis of melanoma-specific T cell precursor frequency prior to and after immunization.

Detailed description: This is a phase I study of melanoma tumor antigen peptide vaccines. The nine amino acid peptides representing HLA-A2 restricted T cell epitope of the melanoma antigen, gp100 will be administered to patients emulsified in Incomplete Freund's Adjuvant, (IFA). The study is designed to evaluate the toxicity, immunologic effects and potential therapeutic role of repeated doses of gp100 peptide vaccines administered subcutaneously.
  Immune reactivity to the gp100 epitope peptides will be monitored in all patients by analysis of melanoma-specific T cell precursor frequency prior to and after immunization.

Eligibility: DISEASE CHARACTERISTICS:
  Metastatic melanoma that is HLA-A2 positive.
  No primary melanoma of ocular or mucosal origin.
  Measurable or resected metastatic disease required.
  PRIOR/CONCURRENT THERAPY:
  BIOLOGIC THERAPY: No prior (greater than 30 days) or concurrent Biologic Therapy.
  CHEMOTHERAPY: No prior (greater than 30 days) or concurrent chemotherapy.
  ENDOCRINE THERAPY: No prior (greater than 30 days) or concurrent hormone therapy.
  No requirement for steroids.
  RADIOTHERAPY: No prior (greater than 30 days) or concurrent radiotherapy.
  SURGERY: Not specified.
  PATIENT CHARACTERISTICS:
  Age: 18 and over.
  Performance Status: ECOG 0 or 1.
  Life Expectancy: More than 3 months.
  HEMATOPOIETIC: No coagulation disorder.
  HEPATIC:
  Bilirubin no greater than 2.0 mg/dL.
  No Hepatitis BsAg antibody.
  RENAL: Creatinine no greater than 2.0 mg/dL.
  CARDIOVASCULAR: No major cardiovascular illness.
  PULMONARY: No major respiratory illness.
  OTHER:
  No previous allergic reaction to incomplete Freund's adjuvant.
  HIV negative.
  No active systemic infection.
  Not pregnant or lactating.

Relevance to patient case: not relevant
Patient case: 45-year-old female with Melanoma. Genetic variant: BRAF (V600E), CDKN2A Deletion. Other conditions: None.

Clinical trial: Interferon Alfa or No Further Therapy Following Surgery in Treating Patients With Stage II, Stage III, or Recurrent Melanoma

Summary: RATIONALE: Interferon alfa may interfere with the growth of the cancer cells. It is not yet known whether interferon alfa following surgery is more effective than surgery alone in treating patients with melanoma.
  PURPOSE: Randomized phase III trial to compare the effectiveness of interferon alfa with no further therapy following surgery in treating patients with stage II, stage III, or recurrent melanoma.

Detailed description: OBJECTIVES: I. Determine the effects of adjuvant low-dose extended-duration interferon alfa on disease-free and overall survival in patients with completely resected malignant melanoma at high risk of recurrence. II. Determine any correlation between patient age or sex and the effects of interferon therapy on disease-free and overall survival. III. Describe the toxic effects of this treatment. IV. Evaluate the economic implications of implementing effective interferon therapy in these patients.
  OUTLINE: This is a randomized study. Patients will be stratified by age, sex, disease status at entry, and participating institution. Patients are randomized to observation only or to receive interferon alfa by subcutaneous injections 3 times weekly for 2 years, or until disease progression or toxicity intervenes. Patients are followed monthly for 6 months, quarterly for 18 months, and every 6 months thereafter.
  PROJECTED ACCRUAL: A total of 1,000 patients will be entered over 5 years.

Eligibility: DISEASE CHARACTERISTICS: Histologically confirmed malignant melanoma definitively resected within 12 weeks prior to entry One of the following categories: Stage II disease (greater than 4 mm Breslow thickness) Stage III disease (regional lymph node involvement) Recurrent non-nodal superficial regional disease (local or in transit) Recurrent regional nodal involvement
  PATIENT CHARACTERISTICS: Able to tolerate interferon No second malignancy except curatively treated: Carcinoma of the cervix Nonmelanomatous skin cancer No pregnant or nursing women
  PRIOR CONCURRENT THERAPY: No prior immunosuppressive therapy, including systemic steroids No prior biologic therapy Recovered from surgery

Relevance to patient case: not relevant
Patient case: 45-year-old female with Melanoma. Genetic variant: BRAF (V600E), CDKN2A Deletion. Other conditions: None.

Clinical trial: Molecular Genetic Lesions and Clinical Outcomes in Children With Acute Lymphoblastic Leukemia

Summary: RATIONALE: The identification of gene mutations may allow doctors to better determine the prognosis of children with acute lymphoblastic leukemia.
  PURPOSE: This clinical trial is studying gene mutations to see if they are related to prognosis of cancer in children with acute lymphoblastic leukemia.

Detailed description: OBJECTIVES:
  -  Examine the prognostic significance of deletion of the p16 (MTS1, CDKN21) gene in children with acute lymphoblastic leukemia.
  -  Attempt to correlate the incidence of specific, nonrandom combinations of molecular genetic lesions with clinical outcome in these patients.
  OUTLINE: Patients are stratified by risk (standard vs high).
  Bone marrow specimens from patients enrolled in CCG-1922, CCG-1882, or CCG-1901 are analyzed for the following genetic lesions: p16 deletion, p14 deletion, and p15 deletion.
  Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment.
  Patients are followed for at least 3 years.
  PROJECTED ACCRUAL: A total of 200 patients will be accrued for this study.

Eligibility: DISEASE CHARACTERISTICS:
  -  Newly diagnosed acute lymphoblastic leukemia (ALL)
  -  Meets criteria for 1 of the following:
  -  Standard risk, as defined by the following:
  -  1 to 10 years old at diagnosis
  -  WBC less than 50,000/mm^3
  -  High risk, as defined by the following:
  -  Less than 1 year old or over 10 years old at diagnosis
  -  WBC greater than 50,000/mm^3
  -  Enrolled on CCG-1922 (standard-risk ALL) or CCG-1882 or CCG-1901 (high-risk ALL)
  PATIENT CHARACTERISTICS:
  Age:
  -  See Disease Characteristics
  Performance status:
  -  Not specified
  Life expectancy:
  -  Not specified
  Hematopoietic:
  -  See Disease Characteristics
  Hepatic:
  -  Not specified
  Renal:
  -  Not specified
  PRIOR CONCURRENT THERAPY:
  Biologic therapy:
  -  Not specified
  Chemotherapy:
  -  Not specified
  Endocrine therapy:
  -  Not specified
  Radiotherapy:
  -  Not specified
  Surgery:
  -  Not specified

Relevance to patient case: not relevant
Patient case: 45-year-old female with Melanoma. Genetic variant: BRAF (V600E), CDKN2A Deletion. Other conditions: None.

Clinical trial: S9903: Whole Brain Radiotherapy Followed By Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases

Summary: RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Stereotactic radiosurgery may kill more tumor cells.
  PURPOSE: Phase II trial to study the effectiveness of radiation therapy followed by stereotactic radiosurgery in treating patients who have brain metastases from malignant melanoma.

Detailed description: OBJECTIVES: I. Estimate the 6 month intracranial progression rate and 6 month overall survival rate in patients with limited brain metastases from malignant melanoma undergoing whole brain radiotherapy followed by stereotactic radiosurgery boost. II. Evaluate the qualitative and quantitative toxic effects of this regimen in these patients.
  OUTLINE: Patients undergo whole brain radiotherapy 5 days a week for 3 weeks, followed 3-5 weeks later by stereotactic radiosurgery. Patients are followed every 3 months until death.
  PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study within 2 years.

Eligibility: DISEASE CHARACTERISTICS: Histologically proven malignant melanoma at primary or any metastatic site Bidimensionally measurable disease by MRI scan Must have 1-6 enhancing brain metastases If at least 2 lesions are present, only 1 lesion may be greater than 3 cm in maximum diameter
  PATIENT CHARACTERISTICS: Age: Not specified Performance status: SWOG 0-2 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: Not pregnant or nursing Fertile patients must use effective contraception
  PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent biologic response modifier or immunotherapy Chemotherapy: No concurrent chemotherapy with whole brain radiotherapy Prior systemic chemotherapy allowed Endocrine therapy: Not specified Radiotherapy: No prior stereotactic or conventional radiotherapy to any field of the brain Surgery: Prior surgical resection of brain metastases allowed (provided 1 or 2 measurable brain metastases remain)

Relevance to patient case: not relevant